Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ainuovirine/lamivudine/tenofovir - Jiangsu Aidea Pharmaceutical

Next Previous
Drug Profile

Ainuovirine/lamivudine/tenofovir - Jiangsu Aidea Pharmaceutical

Alternative Names: ACC 008; ACC-018; Ainuomiti; ANV 150mg + TDF 300mg + 3TC 300mg; ANV+3TC+TDF; Lamivudine/ainuovirine/tenofovir - Jiangsu Aidea Pharmaceutical; Tenofovir/ainuovirine/lamivudine - Jiangsu Aidea Pharmaceutical

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Aidea Pharmaceutical
  • Class Adenine nucleotides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 16 Oct 2024 Phase-III clinical trials in HIV infections (Treatment-experienced) (PO) prior to October 2024
  • 16 Oct 2024 Interim adverse events data from a phase III SPRINT trial in HIV infections presented at the IDWeek 2024 (IDW-2024)
  • 16 Oct 2024 Interim efficacy data from a phase III SPRINT trial in HIV infections presented at the IDWeek 2024 (IDW-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top